Clinical Trial Update: My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update from Genentech evaluating combinations of Herceptin, Perjeta, Tarceva, Zelboraf, Cotellic, Erivedge, Alecensa, and Tecentriq across various…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Tract Cancer
• Bladder Cancer
• Salivary Gland Cancer

Drugs mentioned

• Alecensa (alectinib)
• Cotellic (cobimetinib)
• Erivedge (vismodegib)
• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)
• Tarceva (erlotinib)
• Tecentriq (atezolizumab)
• Zelboraf (vemurafenib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Neoplasms, Solid Tumors | Phase 2 | Status: COMPLETED | Results posted: 2024-07-23